Advances in research on intestinal microecology and clinical outcomes of tumors
1，2SHENG Xiang2， LI Su-yi
1Graduate School of Anhui Medical University， Hefei 230031，Anhui， China；2Department of Nutrition and Metabolism Treatment of Cancer， Provincial Hospital Affiliated to Anhui Medical University， Hefei 230031，Anhui， China
Abstract：The number of parasitic bacteria in the human intestinal tract reached 1014， more than 10 times the number of human cells， including symbiosis and pathogenic microorganisms， which jointly formed the microbial ecological community， namely the intestinal microecology. The intestinal tract provides a place for the growth and reproduction of microorganisms， while microorganisms provide the host with enzymes and biotransformation pathways that are not available in the human body. Therefore， they can decompose the polysaccharide oligosaccharide glycoprotein that is not easily digested by the human body， generate short-chain fatty acids， provide energy for the host， and provide nutrients for the growth and reproduction of intestinal flora. Secondly， intestinal microorganisms produce effects through co-metabolism with the host. For example， multiple metabolic pathways， such as fat emulsification， cholesterol absorption， and enterohepatic circulation， are involved in the catabolism of drugs and other foreign compounds. In addition， intestinal microorganisms form barrier effects against pathogenic microorganisms through their own surface antigens and the host immune system. There is increasing evidence that intestinal microecology plays an important role in the process of tumorigenesis， development and treatment， and has extensive connections with the host. So far， some achievements have been made in the treatment of intestinal microecology intervention with certain means. With the deepening of the research on the relationship between intestinal microecology and tumor， valuable discoveries and inspirations keep emerging. Further exploration and excavation are helpful to improve the understanding of intestinal microecology， hoping to provide more feasible solutions for anti-tumor treatment. This article reviews the advances in clinical outcomes of malignant tumors and intestinal microecology.
盛翔，李苏宜. 肠道微生态与肿瘤临床转归研究进展[J]. 肿瘤代谢与营养电子杂志, 2019, 6(2): 178-182.
SHENG Xiang， LI Su-yi. Advances in research on intestinal microecology and clinical outcomes of tumors. Electron J Metab Nutr Cancer, 2019, 6(2): 178-182.
1.Sekirov I， Russell SL， Antunes LC， et al. Gut microbiota in health and disease. Physiol Rev. 2010；90(3):859-904.
2.Smith K， McCoy KD， Macpherson AJ. Use of axenic animals in studying the adaptation of mammals to their commensal intestinalmicrobiota. Semin Immunol. 2007；19(2):59-69.
3.Hansen CH， Andersen LS， Krych L， et al. Mode of delivery shapes gut colonization pattern and modulates regulatory immunity in mice. J Immunol. 2014；193(3):1213-1222.
4.Wu HJ， Wu E. The role of gutmicrobiota in immune homeostasis and autoimmunity. Gut Microbes.2012；3(1):4-14.
5.de Martel C， Ferlay J， Franceschi S， et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012；13(6):607-615.
6.Kallmeyer J， Pockalny R， Adhikari RR， et al. Global distribution of microbial abundance and biomass in subseafloor sediment. Proc Natl Acad Sci U S A. 2012；109(40):16213-16216.
7.Ojesina AI， Lichtenstein L， Freeman SS， et al. Landscape of genomic alterations in cervical carcinomas. Nature. 2014；506(7488):371-375.
8.Arthur JC， Gharaibeh RZ， Mühlbauer M， et al. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. Nat Commun. 2014；5:4724.
9.Clevers H， Nusse R. Wnt/β-Catenin signaling and disease. Cell. 2012； 149(6):1192-1205.
10.Abreu MT， Peek RM. Gastrointestinal malignancy and themicrobiome. Gastroenterology. 2014；146(6):1534-1546.
11.Hooper LV， Littman DR， Macpherson AJ. Interactions between themicrobiota and the immune system. Science. 2012；336(6086):1268-1273.
12.Garrett WS. Cancer and themicrobiota. Science. 2015； 348(6230):80-86.
13.Hampton T. Gut microbes may shape response to cancer immunotherapy. JAMA. 2018；319(5):430-431.
14.Routy B， Le CE， Derosa L， et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018； 359(6371):91-97.
15.Patterson AD， Turnbaugh PJ. Microbial determinants of biochemical individuality and their impact on toxicology and pharmacology. Cell Metab. 2014；20(5):761-768.
16.Carmody RN， Turnbaugh PJ. Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics. J Clin Invest. 2014；124(10):4173-4181.
17.Viaud S， Saccheri F， Mignot G， et al. Identification of crystals by X-ray diffraction. Science. 2013；342(6161):971-976.
18.Iida N， Dzutsev A， Stewart CA， et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013；342(6161):967-970.
19.Roberts AB， Wallace BD， Venkatesh MK， et al. Molecular insights into microbial β-glucuronidase inhibition to abrogate CPT-11 toxicity. Mol Pharmacol. 2013；84(2):208-17.
20.Wallace BD， Wang H， Lane KT， et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science. 2010；330(6005):831-835.
21.冉曦， 申明强， 曹乐， 等. 腹盆腔放疗诱发肠道微生态失调与肠源性感染的实验研究. 中华放射医学与防护杂志.2015；35(9):641-646.
22.Cui M， Xiao H， Li Y， et al.Faecal microbiota transplantation protects against radiation-induced toxicity. EMBO Mol Med. 2017；9(4):448-461.
23.Nam YD， Kim HJ， Seo JG， et al. Impact of pelvic radiotherapy on gut microbiota of gynecological cancer patients revealed by massive pyrosequencing. PLoS One. 2013；8(12):e82659.
24.Ciorba MA， Riehl TE， Rao MS， et al. Lactobacillus probiotic protects intestinal epithelium from radiation injury in a TLR-2/cyclo-oxygenase-2- dependent manner. Gut. 2012；61(6):829-838.
25.Ciorba MA， Hallemeier CL， Stenson WF， et al. Probiotics to prevent gastrointestinal toxicity from cancer therapy: An interpretive review and call to action. Curr Opin Support Palliat Care. 2015；9(2):157-162.
26.Chitapanarux I， Chitapanarux T， Traisathit P， et al. Randomized controlled trial of live lactobacillus acidophilus plus bifidobacterium bifidum in prophylagxis of diarrhea during radiotherapy in cervical cancer patients. Radiat Oncol. 2010；5:31.
27.Delia P， Sansotta G， Donato V， et al. Use of probiotics for prevention of radiation-induced diarrhea. World J Gastroenterol.2007；13(6):912-915.
28.Nejdfors P， Ekelund M， Westrm BR， et al. Intestinal permeability in humans is increased after radiation therapy.Dis Colon Rectum. 2000；43(11):1582-1587； discussion 1587-1588.
29.Paulos CM， Wrzesinski C， Kaiser A， et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest. 2007；117(8):2197-2204.
30.Quigley EM. Prebiotics and probiotics: their role in the management of gastrointestinal disorders in adults.Nutr Clin Pract. 2012；27(2):195-200.
31.Salazar N， Dewulf EM， Neyrinck AM， et al. Inulin-type fructans modulate intestinal Bifidobacterium species populations and decrease fecal short-chain fatty acids in obese women. Clin Nutr. 2015；34(3):501-507.
32.Likotrafiti E， Tuohy KM， Gibson GR， et al. An in vitro study of the effect of probiotics， prebiotics and synbiotics on the elderly faecal microbiota. Anaerobe. 2014；27:50-55.
33.Kump PK， Grchenig HP， Lackner S， et al. Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis. 2013；19(10):2155-2165.
34.vanNood E， Vrieze A， Nieuwdorp M， et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013；368(5):407-415.
35.Aroniadis OC， Brandt LJ. Intestinal microbiota and the efficacy of fecal microbiota transplantation in gastrointestinal disease. Gastroenterol Hepatol (N Y). 2014；10(4):230-237.
36.Ianiro G， Bibbò S， Gasbarrini A， et al. Therapeutic modulation of gut microbiota: current clinical applications and future perspectives. Curr Drug Targets. 2014；15(8):762-770.
